Pharma H1 exports up 5% to $16.14-bn. as Europe offsets U.S. slowdown

Pharma H1 exports have increased by 5% to $16.14 billion. This growth is largely due to a surge in exports to Europe, which has helped offset the slowdown in the US market. The diversification strategy of Indian pharma companies, which involves expanding their presence in emerging markets, seems to be paying off as exports to regions such as Africa, LAC, and ASEAN gain momentum. This trend is likely to have a positive impact on the overall performance of the Indian pharmaceutical industry.

Why it matters

Pharma exports are up due to market diversification. Europe and other regions are offsetting the US slowdown.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to The Hindu. For information only — not financial advice.